Right to Left Cardiac Shunt Detection

Last updated: November 10, 2015
Sponsor: Cardiox Corporation
Overall Status: Terminated

Phase

3

Condition

Heart Defect

Pentalogy Of Cantrell

Treatment

N/A

Clinical Study ID

NCT01773252
FDS-0005
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the sensitivity and specificity of the Cardiox Flow Detection System (FDS) in identifying an intracardiac right-to-left shunt (RLS) compared to the results of transesophageal echocardiography (TEE).

RLS intracardiac shunts are associated with a number of clinically important syndromes including paradoxical thromboembolism (causing stroke or other systemic infarct), migraine headaches (particularly with aura), desaturation with obstructive sleep apnea, and decompression illness. From a research perspective, the detection of shunts in subjects with these types of syndromes is critical in helping to define the role of RLS in these disease processes. From a clinical perspective, shunt detection will be increasingly important in an era where interventional procedures for repairing cardiac defects are available for subjects determined to be at risk.

The currently accepted reference standard for detection of an intra-cardiac patent foramen ovale/atrial septal defect (PFO/ASD) RLS is a transesophageal echocardiography (TEE), a procedure that is invasive, uncomfortable, and requires conscious sedation.

Alternative options include transthoracic echocardiography (TTE) with injection of agitated saline (with and without Valsalva strain), a procedure that is far less sensitive than TEE due to the echocardiography imaging limitations seen in many adults.

Finally, transcranial Doppler (TCD) with injection of agitated saline (with and without Valsalva strain) is a newer entrant into this arena that does not require sedation or any invasive instrumentation.

The Cardiox Model 100 FDS utilizes an optical sensor positioned on the surface of the subject's skin at the scaphoid fossa of the ear. Next, a predetermined dose of an indicator dye, indocyanine green (ICG), is injected at a predetermined rate into a peripheral antecubital vein of the subject while the subject performs a breathing maneuver called a Valsalva maneuver. The exhalation by the subject into a mouthpiece connected to a pressure transducer via a flexible tubing extension, or its equivalent (ie, performing the Valsalva maneuver), is an essential step for all existing RLS detection methods. The Valsalva maneuver by the subject creates a pressure differential between the right and left sides of the heart. This Valsalva maneuver results in blood flow from the right side of the heart to the left side of the heart through an ASD, and/or causes a PFO, if present, to open, also allowing blood to flow directly from the right side to the left side of the heart without passing through the lungs (pulmonary vasculature) for oxygenation.

The Earpads, including their fluorescence sensor arrays (FSA), are used to measure the relative concentration (ie, fluorescence signal level) of ICG dye in the bloodstream as a function of time. If a premature inflection or peak occurs in the ICG dye concentration level at a time point prior to the rise and fall of the concentration associated with the main bolus of indicator, then a RLS is present in the heart. The amplitude of this premature ICG dye-dilution curve (referred to as "RLS-indicator dilution curve") is used to subsequently quantify the magnitude of the right-to-left shunt by ratiometrically comparing the amplitude of this RLS indicator dilution curve to the amplitude of the main indicator dilution curve associated with that portion of the injected ICG dye that follows the normal pathway from the right side of the heart, through the lungs, and into the left side of the heart (referred to as "normal indicator dilution curve").

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least 18 years of age;

  • Is currently scheduled (within five days of FDS) for a TEE study with agitated salinecontrast (bubble study) or has had a TEE procedure with agitated saline contrast study (bubble study) within the previous 12 months;

  • If the Subject has undergone a shunt closure procedure, the protocol related TEE mustbe conducted greater than 12 months post closure.

  • Is able to read and understand the ICF and has voluntarily provided written informedconsent;

  • Subject is able to perform a successful Valsalva maneuver (obtaining a score of 3stars) using the Cardiox FDS device.

Exclusion

Exclusion Criteria:

  • Subjects with known allergy or sensitivity to ICG or to iodide contrast dye or iodidesincluding medications with high iodine content;

  • Pregnant women or nursing mothers;

  • Subjects scheduled for a radioactive iodine uptake studies (eg, thyroid studies)within one week of completing this study.

Study Design

Total Participants: 141
Study Start date:
November 01, 2012
Estimated Completion Date:
November 30, 2015

Connect with a study center

  • University of Alabama, Birmingham

    Birmingham, Alabama 35249
    United States

    Site Not Available

  • Heart and Vascular Center of Arizona

    Phoenix, Arizona 85006
    United States

    Site Not Available

  • Alliance Research Centers

    Laguana Hills, California 92653
    United States

    Site Not Available

  • UCLA Medical Center

    Los Angeles, California 90095
    United States

    Site Not Available

  • University of Colorado

    Aurora, Colorado 80045
    United States

    Site Not Available

  • Rush University Medical Center

    Chicago, Illinois 60612
    United States

    Site Not Available

  • Tufts Medical Center

    Boston, Massachusetts 02111
    United States

    Site Not Available

  • Columbia University Medical Center

    New york, New York 10032
    United States

    Site Not Available

  • Riverside Hospital

    Columbus, Ohio 43214
    United States

    Site Not Available

  • Methodist DeBakey Heart and Vascular Center

    Houston, Texas 77030
    United States

    Site Not Available

  • Swedish Medical Center

    Seattle, Washington 98122
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.